Handelsavisen
prelaunch
Companies ›Healthcare ›6499.TWO
64
6499.TWO — TPEx Advanced Medical Equipment & Technology

Medeon Biodesign Inc

$86,30
Open in Charts → Attach watcher ⌖
— —
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
8,4B TWD
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-172,3 %
ROE
-45,3 %
Net margin
-159,3 %
Debt / equity
0,08
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Medeon Biodesign Inc develops and commercializes advanced medical equipment and technology, primarily generating revenue through the sale of innovative healthcare solutions.

Business. Medeon Biodesign Inc (6499.TWO) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is listed on the Taiwan Premium Exchange (TPEx). Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-45,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6499.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6499.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Medeon Biodesign Inc (6499.TWO) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm is listed on the Taiwan Premium Exchange (TPEx). Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Medeon Biodesign Inc has a market capitalization of approximately TWD 8.6 billion and a price-to-book ratio of 5.83, indicating a premium valuation relative to its book value. The company's liquidity position is characterized as medium, with a current ratio of 8.21, suggesting strong short-term liquidity. However, the company reported negative operating cash flow of TWD -629.1 million and free cash flow of TWD -628.9 million, indicating significant cash outflows from operations.

    Profitability metrics reveal a challenging financial position. The company reported a net loss of TWD -668.1 million and an operating loss of TWD -722.5 million, resulting in a negative return on equity of -45.27% and a negative return on assets of -37.54%. These figures are below the industry median for profitability metrics, highlighting the company's struggle to generate returns for shareholders and asset utilization.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases the company's exposure to market-specific risks and potential revenue volatility.

    Looking ahead, the company's growth trajectory is uncertain. The current fiscal year is expected to show a decline in revenue, with no specific numeric delta provided. The next fiscal year outlook is similarly unclear, with no projected growth rates or revenue targets disclosed. The company's capital expenditure of TWD -16.9 million suggests limited investment in future growth, which may constrain long-term expansion.

    Risk factors include a negative net cash position after subtracting total debt, which could impact the company's ability to meet short-term obligations. The company's dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's negative operating and free cash flows may necessitate future financing, potentially leading to equity dilution.

    Recent events include the filing of the latest financial statements, which disclose the company's significant operating losses and negative cash flows. No recent earnings call transcripts or other material events are available in the provided data, limiting insight into management's strategic direction or operational updates.

    Key takeaways
    • Medeon Biodesign Inc is trading at a premium to book value with a price-to-book ratio of 5.83.
    • The company is experiencing significant operating losses, with a net loss of TWD -668.1 million and a negative return on equity of -45.27%.
    • The company's liquidity position is medium, with a current ratio of 8.21, but it has negative operating and free cash flows.
    • The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • The company's growth trajectory is uncertain, with no specific revenue growth targets provided for the current or next fiscal year.
    • The company faces a risk of negative net cash after debt, which could impact its ability to meet short-term obligations.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $86,30
    Market cap
    $8.60B
    Enterprise valueⓘ
    $8.71B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    5.8x
    P / Tangible bookⓘ
    5.8x
    Tangible book
    $1.48B
    Net cashⓘ
    -$113.0M
    Current ratioⓘ
    8.2
    Debt / equityⓘ
    0.1
    ROAⓘ
    -37.5%
    ROEⓘ
    -45.3%
    Cash conversionⓘ
    94.0%
    CapEx / revenueⓘ
    -4.0%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy2
    Buy0
    Hold1
    Sell0
    Strong sell0
    12-month price target$200,00 · Median $200,00
    Low $200,00High $200,00
    Operating income · consensus-651,0M TWD
    EPS surprise
    −19,4 %
    reported vs consensus · miss
    Revenue surprise
    −16,2 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$200,00
    Mean$200,00
    Median$200,00
    High$200,00
    Spot$86,30
    +131.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-172,3 %Bottom quartile
    Net Margin-159,3 %Bottom quartile
    ROE-45,3 %Bottom quartile
    Capex / Rev-4,0 %Below median
    D/E0,08Above median
    Cash Conv0,94Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Medeon Biodesign Inc Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6499.TWOCanonical
    TPEx · TWD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage